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Systemic factors including cytokines, cell-free nucleic acids, microvesicles, and platelets are appreciated
as important regulators of adenocarcinoma progression. Research ﬁndings using pre-clinical mouse
models have revealed that many such systemically acting factors are either secreted by or responsive to
peripheral tumors and impact bone and bone marrow (collectively referred to as the bone micro-
environment) to initiate processes that ultimately govern disease progression, even in the absence of
detectable bone metastases. In some cases, cancer-driven modulation of the bone microenvironment
involves mobilization of bone marrow hematopoietic and mesenchymal cells into the circulation that are
subsequently recruited into peripheral tissues and tumors. In other cases, systemic factors alter bone
marrow cell (BMC) differentiation and/or gene expression to render the BMCs pro-tumorigenic even
prior to their mobilization into the circulation. Given their effect on the bone microenvironment, it
stands to reason that such systemic factors might also inﬂuence metastases in the bone; however, this
hypothesis remains to be comprehensively tested. Here, we brieﬂy review what is known, and not
known, about systemic factors that regulate the bone microenvironment and thereby inﬂuence bone
metastases. We also pose a number of currently unanswered questions in this active area of research. A
better understanding of systemic processes that inﬂuence bone metastasis should aid discovery of
therapeutic approaches that aim to eradicate or reduce disease burden in the bone, which is the cause of
signiﬁcant patient mortality and morbidity and is currently incurable.
& 2016 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Is there a role for systemic factors in formation of pre-me-
tastatic niches in the bone?
Bone is a common site for metastatic spread of solid tumors,
particularly for patients with metastatic breast and prostate can-
cers [1]. Here, we speciﬁcally focus on the factors impacting the
bone microenvironment that thereby inﬂuence bone metastasis,
which is the cause of signiﬁcant patient mortality and morbidity
and is currently incurable. At present, very little is known about
systemic processes that inﬂuence bone metastasis. Increasingly,
efforts are being directed toward this area of investigation with the
notion that a better understanding of systemic processes that in-
ﬂuence bone metastasis should aid discovery of therapeutic ap-
proaches that aim to eradicate or reduce disease burden in the
bone.GmbH. This is an open access art
igham & Women's Hospital,
.
. Ubellacker),Results from studies using pre-clinical metastasis models have
revealed that primary tumor-derived circulating factors can affect
various tissue microenvironments, even in the absence of ob-
servable metastases to those tissues, to make them a more hos-
pitable environment for seeding and colonization of tumor cells
that eventually disseminate from the primary tumor [2,3]. This
process was termed “pre-metastatic niche” formation and most of
what is known in this regard was gleaned from pre-clinical studies
of lung metastasis. Much less is known about cancer-derived cir-
culating factors that establish pre-metastatic niches in the bone.
On one hand, the paucity of information may be due to the fact
that there are very few bone metastasis models currently available
to researchers. On the other hand, the bone microenvironment
may inherently provide a favorable environment for disseminated
tumor cells, thus eliminating the need for pre-metastatic
modulation.
The fact that disseminated tumor cells are frequently detected
in bone marrow aspirates of cancer patients who are tested in this
manner [4] favors the idea that disseminating tumor cells ﬁnd a
ready-made niche in the bone microenvironment. Traditionally,icle under the CC BY-NC-ND license
Fig. 1. Some of the systemic factors involved in dissemination and outgrowth of bone metastases. In the pre-metastatic bone, primary tumor-derived circulating factors can
affect various tissue microdomains (hematopoietic cells, mesenchymal stromal cells, osteoblasts, osteoclasts, and vascular cells) to make them a hospitable environment for
seeding of tumor cells that eventually disseminate from the primary tumor. After tumor cells have disseminated to bone, primary tumor-derived factors and other circulating
cytokines of unknown origin can inﬂuence colonization of those tumor cells. Likewise, the tumor cells within the bone microenvironment secrete factors that disrupt normal
bone homeostasis to fuel metastatic progression. Abbreviations: CAF, cancer-associated ﬁbroblast, see Table 1 for growth factors.
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the bone that support tumor cell seeding and outgrowth via
paracrine interactions, and can be comprised of hematopoietic
cells, a variety of mesenchymal stromal cells, osteoblasts, osteo-
clasts, and/or vascular cells [1] (Fig. 1). Within these micro-
domains, a number of chemokines and integrins that are en-
dogenously expressed by various bone stromal cells to regulate
mobilization and homing of hematopoietic cells are also thought
to aid tumor cell recruitment to bone [1]. For example, bone
stroma derived CXCL12 (SDF-1α) has been demonstrated to recruit
CXCR4-expressing neuroblastoma cells [5]. Likewise, differentiat-
ing osteoclasts secrete CCL22, which was shown to promote bone
metastasis of CCR4-expressing breast cancer cells [6]. Additionally,
osteoblasts express a number of factors, including CCL12, which
has been correlated with increased tropism of CCR7-expressing
metastatic breast cancer cells [7].
More recently, primary tumor driven generation of a bone pre-
metastatic niche was observed in a mouse model of estrogen re-
ceptor-negative breast cancer metastasis. Speciﬁcally, lysyl oxidase
(LOX) secreted into the circulation from hypoxic primary breast
tumors disrupted bone homeostasis, thereby inducing osteolysis
[8]. The osteolytic microdomains within the bone served as niches
for subsequent metastatic tumor cells, and bisphosphonate ad-
ministration in the pre-metastatic setting prevented development
of metastatic disease. This work is the ﬁrst reported observation of
breast cancer induced osteolytic action-at-a-distance (breast can-
cers frequently induce osteolysis following their dissemination to
bone, as we discuss later). These ﬁndings, if further supported,
have important clinical implications and should prompt further
investigation into systemic modulation of bone-speciﬁc pre-me-
tastatic niches.2. Do primary tumors that impact the bone microenviron-
ment also inﬂuence bone metastases?
Interestingly, bone is a conduit during pre-metastatic niche
formation in visceral tissues in nearly all reported studies to date
[2]. In other words, pre-metastatic niche formation in extra-oss-
eous organs involves mobilization, modiﬁcation, and recruitment
of bone marrow derived cells (BMDCs) that help create the niche.
Even before the discovery of pre-metastatic niches, investigation
into the role of BMDCs in primary tumor progression and metas-
tasis was an active area of research, as it still is today.
Numerous studies have shown that tumor-derived systemically
acting factors impact the bone microenvironment to expand and
mobilize bone marrow cells (BMCs) into the circulation that are
subsequently recruited to tumor sites where they instigate various
processes that support tumor progression [9,10] (Table 1). For
example, tumor-derived granulocyte colony-stimulating factor (G-
CSF) and interleukin-1β (IL1β) mobilize tumor-supportive
CD11bþ/Gr1þ myeloid cells from the bone marrow into circula-
tion, while vascular endothelial growth factor-A (VEGF-A) and
placental growth factor (PIGF) release hemangiogenic BMCs
(VEGFR1þ cells) from the bone marrow into circulation [9]. Breast
cancer-associated ﬁbroblasts (CAFs) have been demonstrated to
secrete CXCL12, which induces the release of pro-angiogenic
hematopoietic progenitor cells into the circulation [11].
Tumor-derived microvesicles–membrane-bound particles re-
leased from a primary tumor that carry lipids, proteins, mRNAs
and miRNAs–could also modulate cells in the bone micro-
environment [12]. For example, melanoma exosomes were shown
to ‘educate’ bone marrow progenitor cells toward a pro-metastatic
phenotype [13]. More recently, OPN carried through the
Table 1.
Some of the bone modulating factors that impact cancer progression.
Factor Source Mechanism of action
SDF-1 α/CXCL12 Osteoblasts; CAFs Provides a supportive stromal microenvironment for CXCR4-expressing cancer cells [5]. CAFs secrete CXCL12,
which induces the release of pro-angiogenic hematopoietic progenitor cells into the circulation [11]
CCL22 Osteoclasts Promotes bone metastasis of CCR4-expressing breast cancer cells [6]
CCL12 Osteoblasts Promotes bone tropism of CCR7-expressing breast cancer cells [7]
Angiopoietin DTCs Promotes metastasis to the bone by enhancing tumor-cell responsiveness to CXCL12 via CXCR4, and potentially
other unknown mechanisms [12]
OPN Primary tumor and
microvesicles
Microparticle-derived OPN mobilizes pro-angiogenic cells from the bone marrow in response to chemotherapy
[14]; necessary for pro-tumorigenic function of Sca1þ/ckit-CD45þ hematopoietic bone marrow cells that are
recruited to the tumor microenvironment [16]
Lysyl Oxidase Primary tumor and DTCs Generates pre-metastatic niche in bone through disruption of bone homeostasis [8]
VEGF-A DTCs Releases hemangiogenic VEGFR1þ cells from the bone marrow into circulation [9]
G-CSF DTCs Mobilizes tumor-supportive myeloid cells from the bone marrow into circulation [9]; upregulates pro-angio-
genic factors in myeloid cells [15]
IL1β DTCs Mobilizes tumor-supportive myeloid and myeloid derived suppressor cells from the bone marrow into circu-
lation [9]
PIGF DTCs Releases hemangiogenic VEGFR1þ cells from the bone marrow into circulation [9]
TGF-β DTCs, Bone ECM Mobilizes myeloid cells from the bone marrow [12]; Latent TGFβ released from bone ECM stimulates cytokine
production in DTCs [18]
IL-6, IL-8, IL-11 Primary tumors, DTCs,
osteoblasts
Accelerates growth factor release from bone matrix via upregulation of RANKL/RANK, and thus fuels the vi-
cious cycle of tumor progression [1]
PTHrP DTCs Promotes osteoclast maturation or stimulates osteoblast secretion of IL-6 and RANK, thus propagating a vicious
cycle of tumor outgrowth and bone breakdown [18]
MMP2, MMP9 DTCs Cause release of TGF- β and other factors from the bone marrow microenvironment that induce DTC pro-
duction of a variety of cytokines, most notably PTHrP [18]
GDF15 CAFs Promotes metastatic outgrowth in the lung [20]
Pro-angiogenic factors Cancer-associated platelets Platelets take up factors secreted by primary tumors to aid angiogenesis in disseminated tumors at distant sites
[12]
SDF-1 Stromal cell-derived factor 1; CCL22 Chemokine (C-C motif) ligand 22; CCL12 Chemokine (C-C motif) ligand 12; OPN Osteopontin; VEGF-A vascular endothelial growth
factor A; G-CSF Granulocyte colony stimulating factor; PIGF Placental growth factor; TNF-α Tumor necrosis factor α; TGF-β Transforming growth factor β; IL-6 interleukin 6;
IL-8 Interleukin 8; IL-11 Interleukin 11; PTHrP Parathyroid hormone-related protein; MMP matrix metalloproteinase; ECM extracellular matrix; GDF15 growth/differentiation
factor 15; CAFs cancer-associated ﬁbroblasts; DTCs disseminated tumor cells. While many of these factors have pleiotropic effects in various contexts, we limit descriptions to
bone-speciﬁc effects that are known to affect cancer progression.
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in response to chemotherapy, was necessary for mobilizing pro-
angiogenic cells from the bone marrow [14].
It is becoming increasingly apparent that tumor-derived factors
can also alter certain BMCs by affecting their gene expression even
prior to their mobilization into the circulation [12] (Table 1).
Murine cancer models revealed that a subset of myeloid cells
upregulated pro-angiogenic factors in response to tumor-derived
G-CSF [15]. In studies of mouse xenograft models, tumor-derived
soluble OPN, which functions as an inﬂammatory cytokine, ren-
dered Sca1þ/cKit-/CD45þ hematopoietic BMCs pro-tumorigenic
by modulating gene expression prior to their mobilization into
circulation [16].
Based on the seemingly intimate relationship between primary
cancers and the bone microenvironment, and given that certain
tumors can act in an endocrine fashion to generate pro-tumori-
genic hematopoietic BMCs, it stands to reason that these same
BMCs would provide support to tumor cells that land in the bone.
However, this hypothesis remains to be tested, thus representing
an area where additional research is necessary. In this context, it is
likely that many more tumor-derived systemic factors that modify
BMCs remain to be identiﬁed.3. Do cancer-dependent systemic factors inﬂuence tumors that
have disseminated to bone?
Despite the frequency with which disseminated tumor cells
(DTCs) are found in the bone marrow of cancer patients, the sig-
niﬁcance of these cells is unknown, as a considerable number of
these patients never develop overt metastatic disease [4]. Such
ﬁndings support the concepts of metastatic inefﬁciency and tumor
dormancy [17] and suggest that while the bone microenvironmentmay be conducive to initial dissemination and survival of tumor
cells, other processes are required to promote disease progression.
Certainly, dynamic interactions between DTCs and stromal cells
within the bone microenvironment disrupt bone homeostasis,
which is normally tightly controlled, to fuel metastatic progression
[18] (Table 1). For example, it is well established that osteolytic
breast cancer DTC-derived factors, such as matrix metalloprotei-
nases, cause the release of latent TGF-β from the bone micro-
environment. This, in turn, induces DTC production of a variety of
cytokines, most notably parathyroid hormone-related protein
(PTHrP), which either promotes osteoclast maturation or stimu-
lates osteoblast secretion of IL-6 and RANKL thus propagating a
vicious cycle of tumor outgrowth and osteolytic bone breakdown
[18]. Tumor cells can also directly secrete interleukins (speciﬁcally
IL-6, IL-8, and IL-11) to increase osteoclastogenesis, and thus fuel
the vicious cycle of tumor progression [1]. Likewise, osteoblastic
DTCs, such as those that metastasize from prostate cancers, initiate
paracrine interactions within the bone microenvironment that
serve to promote their growth [18].
The fact that many of the same tumor-supportive cytokines
that are secreted by DTCs within the bone microenvironment are
also secreted by the primary tumors that spawned them begs the
question of how much inﬂuence the primary tumor has on DTCs in
the bone. The answer may have clinical relevance, considering that
patients who develop metastatic disease after surgery and treat-
ment of their primary cancer clearly had DTCs in the periphery at
the time of their initial diagnosis. Indeed, pre-clinical models of
the early phases of metastatic disease, when patients harbor in-
dolent DTCs at a time when their primary tumor is present, have
provided important insights into systemic cross talk between
distantly located tumors. For example, early studies of chemically-
induced cancers revealed that some tumors establish an immune-
permissive environment for the outgrowth of otherwise
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termed “systemic instigation”, certain primary tumors promote the
outgrowth of otherwise indolent lung metastases by secreting
factors that cause mobilization and recruitment of BMDCs that
aid metastatic outgrowth [12]. In the case of systemic instigation
by triple-negative breast cancer, primary tumors secrete OPN into
the circulation, which is necessary for rendering BMCs pro-tu-
morigenic. In systemic instigation models of luminal breast
cancer, tumor-derived cytokines and growth factors are taken up
by circulating platelets that cooperate with BMDCs to promote
angiogenesis in the distant tumors. In addition to tumor cells,
cells in the primary tumor microenvironment can impact distant
metastasis. For example, cancer activated ﬁbroblasts secrete
growth/differentiation factor 15 (GDF15, also known as macro-
phage inhibitory cytokine-1, MIC-1, a member of the TGF-β fa-
mily of growth factors) to promote metastatic outgrowth in the
lung [20].
Although it stands to reason that primary tumor derived sys-
temic factors that render BMCs pro-tumorigenic would almost
certainly impact tumor cells that had metastasized to bone, sys-
temic instigation of bone metastasis has not been reported. Re-
search in this area seems crucial for identifying therapeutic ave-
nues designed to restrict growth of DTCs in the bone.4. Conclusions and questions
The past decade has seen a signiﬁcant expansion in our
knowledge about the intimate, yet long-distance relationship be-
tween various cancers and the bone microenvironment (Fig. 1).
Nevertheless, surprisingly little is known about whether or
how such systemic endocrinal interactions impact bone metas-
tases. Development of better pre-clinical models of bone metas-
tasis, with validation in clinical studies, should help guide inter-
ventions aimed at inhibiting underlying systemic signaling cas-
cades, if they exist, and could offer clinical beneﬁt for cancer pa-
tients. Hence, some critical questions in this active area of research
remain unanswered:
 Does the bone environment need to be modiﬁed in order to
establish a hospitable niche for disseminating tumor cells?
 What systemic factors, if any, are necessary and/or sufﬁcient to
generate tumor-supportive or tumor-inhibitory niches in the
bone marrow?
 How do modulation of osteoblast/osteoclast, hematopoietic,
vascular, and/or bone stromal compartments affect bone
metastasis?
 What lessons can be learned from studying metastatic niches in
other visceral organs to inform bone metastasis?
 Are there primary tumor-derived systemic instigation factors
that promote outgrowth of dormant DTCs in the bone?
 Are factors secreted by bone DTCs to inﬂuence the bone mi-
croenvironment also secreted by primary tumors from a dis-
tance to inﬂuence bone metastasis?
 Do physiological conditions that impact the bone micro-
environment, such as pregnancy, wound healing, bone re-
modeling, and aging, also inﬂuence bone metastases? What is the impact of systemic regulation of immune function
on metastatic colonization in the bone?
 Do bone-modulating drugs (denosumab, bisphosphonates, ﬁl-
grastim, plerixafor, etc.) also inﬂuence bone metastases?
 What therapeutic interventions could be developed to inhibit
systemic signaling mechanisms of cancer metastasis to the
bone?
 What patient biomarkers may be used to indicate the tumor-
speciﬁc systemic environment in the bone, and subsequent re-
sponse to adjuvant therapies?Acknowledgement
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